

October 22, 2021



Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Gothenburg, October 22, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has appointed professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor to the company.

Dr. Gunilla Enblad is a Senior Consultant in Oncology since 2000 and was Head of Department at the Oncology Clinic at Uppsala University Hospital between 2004 and 2012. Enblad is Professor in Oncology at Uppsala University since 2013 and author of 137 scientific publications having in total more than 3000 citations.

- We are proud to have Gunilla Enblad as a scientific advisor and principal investigator in the upcoming clinical phase I/II study in blood cancer, which we plan to start next year. Gunilla's experience in the field will be very valuable, in everything from study design to scientific advice, says Jamal El-Mosleh, CEO of Elicera.

Gunilla Enblad is a member of the Swedish Hodgkin lymphoma group since many years and acted as their Chairman between 2004 and 2013. Enblad's current research is focused on CAR T-cell therapy and in 2014 she treated the first patient in Europe with CAR T-cells. She has been the principal investigator for one completed phase I/IIa trial using CD19 CAR T-cells for treatment of refractory or relapsed B-cell malignancies (lymphomas and leukemias) and a completed clinical phase II trial.

During the second half of 2022, Elicera intends to start a clinical phase I/II study with the drug candidate ELC-301 for the treatment of B-cell lymphoma in which Gunilla Enblad will act as principal investigator.

About ELC-301

ELC-301 a CD20-directed CAR T-cell therapy for the treatment of B-cell lymphoma. ELC-301 has been armed with the company's iTANK-platform for activation of CD8 + killer T-cells against the whole set of relevant target antigens on tumor cells, thus generating a powerful parallel immune response against cancer. A clinical phase I/II study is expected to be initiated during the second half of 2022 in collaboration with Uppsala University.

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The company has four drug candidates in

development, two CAR T-cells and two oncolytic viruses, which are based on research conducted by Professor Magnus Essand's research group at Uppsala University. In addition, Elicera has a fully developed technology platform, iTANK, which can be used to optimize the effect of all CAR T-cell therapies under development and activate killer T-cells against cancer. Elicera's share (ELIC) is listed on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.

For more information, please visit www.elicera.com